
    
      This clinical study is a prospective, multicenter, randomized, controlled study evaluating
      SIR-Spheres Y-90 resin microspheres followed by cisplatin-gemcitabine (CIS-GEM) chemotherapy
      vs. CIS-GEM chemotherapy alone as first-line treatment of patients with unresectable
      intrahepatic cholangiocarcinoma.

      Randomized patients will be followed until death, withdrawal of consent, or until end of
      study.
    
  